US Capital Global Securities Announces $50MM Equity Offering for Pharmaceutical Innovator, Bridge Therapeutics

RYLTI Inc.

Explore an exclusive investment opportunity in Bridge Therapeutics, a pharmaceutical company pioneering innovative solutions in chronic pain treatment and opioid use disorder.

SAN FRANCISCO, MAY 2024 – US Capital Global Securities LLC, an SEC-registered affiliate of renowned global financial group US Capital Global, is pleased to present eligible investors with a unique investment opportunity to participate in an investment round of up to $50 million for Bridge Therapeutics, Inc. (“Bridge”). Bridge is late-stage development company pursuing FDA approval of BT-205 for the treatment of chronic pain in opioid-experienced patients and BT‑219 for opioid use disorder.

Headquartered in Birmingham, Alabama, Bridge’s mission is to enhance healthcare through safer and more effective therapies for chronic pain and opioid use disorder (OUD). Bridge has already raised over $9 million, of which the last $2.5 million has come from 44 pain specialists. Currently, it is seeking a $50 million equity investment for manufacturing, distribution, licensing, clinical trials, regulatory consulting, and marketing initiatives.

“Bridge addresses a root cause of the opioid crisis, namely the need for strong, yet safe pain relief.  We do this by improving an existing drug, buprenorphine, using Zydis® delivery technology from Catalent (NYSE: CTLT). Zydis cuts the dissolution time of existing buprenorphine films and tablets 99-fold, from roughly 10 minutes to just a few seconds. Rapid dissolution and pleasant taste should make buprenorphine a more attractive therapy for moderate-to-severe chronic pain and opioid addiction than is currently available,” explained Tim Peara, President of Bridge.

“We believe the market opportunity is vast, estimated at approximately $40 billion, with a relatively swift and inexpensive road to market utilizing the FDA’s 505(b)(2) pathway,” noted Charles Towle, CEO at US Capital Global Securities LLC. “In addition, Bridge protects its pipeline with four product patents, two granted and two pending, coupled with possible joint patents through licensing agreements. These prime Bridge for expansion. Eligible investors now have a unique opportunity to participate in this $50 million equity offering.”

About Bridge Therapeutics, Inc.

Bridge Therapeutics, Inc. (“Bridge”) is a late-stage development company pursuing FDA approval of BT-205 for the treatment of chronic pain in opioid-experienced patients, and BT‑219 for opioid use disorder (OUD). Bridge’s mission is to improve the healthcare of millions of patients through safer and more effective therapies for chronic pain and OUD. To learn more, visit www.bridgetherapeutics.com.

About US Capital Global

US Capital Global Securities LLC (“USCGS”) serves as the FINRA-member broker-dealer division of US Capital Global, specializing in facilitating growth-stage investments. Since 1998, US Capital Global has been dedicated to providing lower middle market businesses and investors with sophisticated investment opportunities. For further details about US Capital Global Securities or this investment opportunity, contact Frank Villarreal, Managing Director and Partner, at fvillarreal@uscapital.com or call +1 415-350-4092.

Disclaimer: USCGS or its affiliates may provide advice to, be compensated by, have other business relationships with, or may from time to time acquire, hold, or sell a position in the securities of the issuers mentioned herein. Any offer or solicitation shall be made only pursuant to the confidential private placement memorandum. View USCGS’ Form CRS at www.uscapglobalsecurities.com/crs.html



Download a PDF of this Press Release



Sign up to our weekly newsletter

Click here

Contact our Media department

Click here